Introduction
Cytokine s play a pivotal role in modulation of the immune resp onse follow ing solid organ transplantation. A distinc t array of c ytokine s produc ed by tw o subse ts of CD4+ he lper T ce lls, Th 1 and Th 2 , dictate s induc tion and regulation of c ellular and humoral immunity. The Th 1 subset sec re te s IL-2, IL-3, IFN-g and TNF, w hich subse que ntly also induc e ex pre ssion of adhe sion molec ule s, w here as Th 2 c ells produce IL-4, IL-5, IL-6 and IL-10.
1,2 The Th 1 /Th 2 paradigm is based on the hypothesis that a Th 1 immune re sponse is dete cted in hosts undergoing rejec tion w he reas an immune patte rn that deviate s tow ards a Th 2 response is assoc iated w ith allograft toleranc e . 2 Incre ase d plasma TNF le vels have be en show n to prec ede re je ction in both liver and kidne y transplant patie nts and IL-2 and IFN-(have be en consis te ntly de te c te d in hosts undergoing unmodifie d ac ute reje ction. 3 -6 IL-4 has be en note d to be prefe re ntially assoc iated w ith allograft engraftme nt. 7 -9 Ye t, ele vated IL-4 levels are also e vident in rejec ting p atie nts, most notably in those w ith spontaneously re solving rejec tion. 10 ,11 This increase in IL-4 le vels occ urs at a later time point than the inc re ase in IL-2 le ve ls, like ly indicating amelioration of the rejec tion e pisode . Further studies have suggeste d that rather than absolute le ve ls of individual cytokines it is the ratio of Th 1 /Th 2 c ytokines w hich se rves in dete rmining allograft rejec tion or toleranc e . 9 In order to further e luc idate the efficacy of cytokine monitoring in predicting re je ction w e se rially monitored Th 1 cytokines IL-2 and IFN-g , the Th 2 cytokine IL-4 and ICAM-1 leve ls in liver transplant patie nts during the first w ee k post-transplant.
Materials and Methods

Patients
Tw enty-tw o patients undergoing an orthotopic liver transplant w ere studied. Plasma samples w ere obtained from e ach patie nt w ithin 4 h after liver perfusion and on postoperative days (POD) 3 and 6.
Data analysed include d: primary immunosuppre ssion, e arly graft function (poor e arly graft function w as de fine d as prothrombin time (PT) > 18 s on POD 2 and pe ak aspartate aminotransfe rase (AST) or alanine aminotransferase (ALT) > 2500 units during the first 3 postoperative days ), evide nce of infe ction (based on cultures of blood, sputum, urine , w ounds and drains, cytomegalovirus (CMV) se rology and CMV c ulture s ) and his tologic ally proven re je ction during the first 2 w e eks post-transplant. 
Data analysis
For e ach cytokine mean patients' absolute levels at 4 h post-pe rfusion (baseline leve ls ) w ere compared w ith me an absolute levels at 3 and 6 POD. Data w ere also analysed by c alc ulating the mean change in cytokine levels, e.g. e ach patie nt's baseline levels at 4 h postperfusion w e re ex p re sse d as 100%, and the patient's cytokine le ve ls at 3 and 6 POD ex pre sse d as pe rce ntage of base line . The p erce ntage inc re ase from baseline to le vels at POD 3 and 6 w as compare d among patie nts w ith and w ithout re jec tion and among those rec eiving cyclosporine A (CsA) or OKT 3 as primary immunosuppression. Results w e re compared by the Mann-Whitne y te st and by one-w ay analysis of variance (ANOVA).
Results
Of the patie nts studie d there w ere 11 males and 11 females, w ith an age range of 49.4 ± 8.9 (mean ± SD). Indication for transplantation w as he patitis C virus (HCV) c irrhosis in 13 patients, hepatitis B virus (HBV) in tw o, cryptogenic cirrhosis in one, primary biliary cirrhosis in tw o, autoimmune live r disease in tw o, fulminant liver failure in one, and primary sclerosing cholangitis in one. This diversity pre cluded data analysis ac cording to primary liver disease. The primary immunosuppressive drug w as cyclosporine in 15 patients and OKT 3 in se ve n patients.
In nine patie nts no rejec tion ep is odes w ere docume nted w ithin the first 12 days post-transplant. In 13 patients re je ction w as diagnosed during the first 12 days post-transplant (in six patients rejec tion w as diagnosed during days 6-8 post-transplant.
Cytokines
IL-2 le vels w ere non-de te ctable in all plasma samples studied. sIL-2R le ve ls inc reased from 74.8 ± 11.8 pmol/ml (me an ± standard e rror ) at 4 h postperfusion to 171.4 ± 23 pmol/ml at POD 3-6, P < 0.001. The mean perce ntage increase from base line levels w as significantly higher in patients w ith OKT 3 induc tion c ompare d w ith c yclosporine treate d patients: 531.5% ± 140.8 vs. 237.7% ± 32.3, P < 0.001. Me an perce ntage incre ase from base line did not differ in the prese nce or absenc e of rejection (305.3% ± 70.7 vs. 366.6% ± 104.4 ).
Mean levels of IFN-g at POD 3-6 w ere significantly inc re ased compared w ith post-perfusion leve ls; from 111 ± 28 pg /ml post-perfusion to 163 ± 39 pg /ml at POD 3-6, P < 0.05. Me an perc entage inc rease from baseline did not correlate w ith rejec tion episodes (rejection vs. no-re je ction: 181.1% ± 50.1 vs. 206.4% ± 68.7 ) or immunosuppressive therap y (CsA 231.2% ± 47.8 vs. OKT 3 227.6% ± 85.4 ).
ICAM-1 levels at 3-6 days post-transplant w ere significantly higher than baseline post-perfusion le vels; 431 ± 38.6 pg /ml vs. 223 ± 44.0 pg /ml, P < 0.001.
No correlation w as observe d be tw een pe rcentage inc re ase in IFN-g le vels and the increase in ICAM-1 levels (for all patie nts R 2 = 0.09, in patients w ith rejec tion R 2 = 0.02 ). IL-4 le ve ls w ere unchanged during the time period studied. Mean base line le ve ls 678.5 ± 46.8 pgm /ml vs. 650.5 ± 50.1 pg /ml at POD 3 -6. Le vels w ere similar in the pre sence or absence of rejec tion and in OKT 3 and CsA-treated patients.
The ratios of IL-4 /IFN-g remained unchange d over time ; 14.3 ± 3.7 post-pe rfusion vs. 13.1 ± 5.6 at POD 3-6. Although the ratio of IL-4 /IFN-g at both baseline and POD 3 -6 w as low er in patients ex perie ncing early rejection c omp ared w ith patie nts w ithout re je ction, differenc es w ere not statistic ally significant.
Discussion
In post-live r transplant patients serial monitoring of plasma Th 1 c ytokine s IL-2 and IFN-g , Th 2 cytokine IL-4 and the adhe sion molecule ICAM-1 during the first w eek post-transplant did not enable pre dic tion of early rejec tion.
In our patients IL-2 levels w ere non-detectable in all p lasma sample s studied. IL-2 w as non-dete ctable e ve n at base line measureme nts w ithin the first few hours post-liver perfusion de noting that the initia l dose of immune suppressive therapy (CsA or OKT 3 ) is sufficie nt to abolish IL-2 rele ase from activate d lymphoc ytes. IL-2 le vels w ere similarly nonmeasurable in the 13 patie nts in w hom e arly rejec tion w as diagnosed. An increase in IL-2 levels is freque ntly observe d in transplant recipie nts ex pe rie ncing episodes of reje ction 1 0,12,1 3 but have not be en found, in all studie s, to be suffic ie ntly reliable to diagnose or ex clude re je ction. 5 Inde ed, Baan e t a l. 1 1 note d intragraft IL-2 mRNA ex pression in only 36% of postlive r transplant patients w ith rejection. In re nal transplant recipie nts studied during the first 14 days post-transplant, IL-2 levels, w hen measurable, w ere predictive of impending graft rejec tion and increase d a mean 2.8 days prior to clinical diagnosis of rejec tion. 10 Although rejec tion w as diagnosed in six of our patients as e arly as days 6 -8 post-transp lant, no ele vation in IL-2 leve ls w as e vide nt.
Soluble IL-2 re ce ptor le ve ls w ere incre ase d at POD 3-6 in all p atie nts, both in the absence and presenc e of rejec tion. The highe st levels w ere me asure d in patients w hose primary immunosuppre ssion w as OKT 3 , the reby likely de noting the marked degree of cytolysis w hich occ urs follow ing OKT 3 administration.
Monitoring of IFN-g le ve ls w as also of no predictive value regarding e arly rejec tion. Le ve ls increase d to a similar de gree in all patients during the first w ee k post-transplant corroborating findings of a previous study in renal transplant patients in w hom rise s in IFN-g levels during the first 2 w ee ks post-transplant w as not associated w ith rejec tion.
14 IFN-g is one of the major induc ers of ICAM-1 but change s in IFN-g levels did not correlate w ith changes in ICAM-1 levels (analysed both for all p atie nts and for the rejec tion group ). Although signific ant e le vations in ICAM-1 levels have bee n rep orte d in renal transplant patients 2 -3 days prior to diagnosis of clinical rejec tion, 14 in our patie nts rejec tion w as not ac companied by change s in ICAM-1 levels. Multiple factors appear to affec t plasma ICAM-1 levels; preope rative ischaemic injury, repe rfusion injury, graft dysfunction and infe ctions. 15 -17 Of the infec tious pathogens, CMV is remarkable in its ability to upregulate ex pression of adhesion molecules on infe cted cells. 1 8 Among our patients, se ven had infectious e pisode s diagnose d during the study period and although in none w as CMV infe ction diagnosed three w e re CMV negative prior to transp lantation from a CMV positive donor. Thus, the nume rous variable s affec ting p lasma ICAM-1 leve ls pre clude the use of this parame te r in predicting rejec tion. Our findings point to immunosuppressive therap y as a major dete rminant of ICAM-1 le ve ls as these w e re significantly low er in patients rec eiving primary immunosuppression w ith OKT 3 .
Le ve ls of the Th 2 cytokine IL-4 remained relatively stable throughout the first w e ek post-transplant in all patients studie d, and did not c orre late w ith the abse nce or prese nce of rejec tion. A pre vious study, in renal transp lant rec ip ie nts, reporte d that the highe st IL-4 leve ls are dete cted late in the c ourse of clinical rejec tion sugge sting that the rise in IL-4 levels coinc ide s w ith resolution of the re je ction epis ode. 1 0 This observation is in acc ord w ith findings in liver transplant patients in w hom intragraft IL-4 mRNA ex pre ssion w as dete cte d in 70% of biopsie s w ith histologic al evidence of rejec tion obtaine d from patients w ithout clinical signs of reje ction. In contrast, IL-4 mRNA ex pression w as prese nt in only 19% of biopsie s w ithout rejection and 18% of biopsie s w ith histological e videnc e of re je ction and concurrent graft dysfunction. 1 1 Thus, in our patients, as plasma IL-4 le ve ls w ere de te rmine d not later than POD 6, a later rise in IL-4 may have been misse d. Interestingly, Gorc zynski e t a l. 19 observe d e quivale nt transc ription of IL-4 in peripheral blood lymphocytes and live r biopsie s of all live r transplant patie nts, regardless of re jec tion status. Furthermore, le ve ls of anothe r Th 2 cytokine, IL-10, w hich are ex pec te d to rise in patie nts w ith unc omplic ate d transplants do not differ in rejecting and non-re je cting patients nor does intragraft ex pression of IL-10 mRNA differ betw e en uncomplicate d transplants, acute and chronic re je ction or normal liver c ontrols. 20 The late rise in IL-4, c ompatible w ith a role for Th 2 ce lls in suppressing the Th 1 depe nde nt immune response, has sugge ste d that the Th 1 /Th 2 balanc e may be more p re dic tive of the immune response than individual c ytokine levels. Ye t, in p ost-live r transp lant childre n the IFN-g /IL-4 ratio c ould not disc riminate betw e en infec tious episode s, othe r than CMV and rejec tion. 21 In our study, although in patients w ith rejec tion the IFN-g /IL-4 ratio w as higher than in nonrejec ting p atie nts, differe nce s did not reach statistic al significance .
In summary, our observations do not support a role for cytokine monitoring, during the first w eek post-OLT, in predicting e arly re je ction. Plasma levels of sIL-2R, ICAM-1, IFN-g , IL-4 and the ir ratios do not correlate w ith rejec tion. Notably, immunosuppre ssive therapy is the pre dominant fac tor affecting plasma sIL-2R and ICAM-1 levels after live r transplantation.
